Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases

被引：11

作者：

Vefring, Hege K. ^{[1
]}

Gruber, Franz X. E. ^{[3
,4
]}

Wee, Line ^{[1
]}

Hovland, Randi ^{[5
]}

Hjorth-Hansen, Henrik ^{[6
,7
]}

Dahl, Tobias Gedde ^{[8
]}

Meyer, Peter ^{[2
]}

机构：

[1] Stavanger Univ Hosp, Dept Med Biochem, NO-4022 Stavanger, Norway

[2] Stavanger Univ Hosp, Dept Hematol & Oncol, NO-4022 Stavanger, Norway

[3] Univ Tromso, Inst Pharm, Tromso, Norway

[4] Univ Hosp No Norway, Dept Immunol & Transfus Med, Tromso, Norway

[5] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway

[6] Norwegian Univ Sci & Technol, Univ Trondheim Hosp, St Olavs Hosp, N-7034 Trondheim, Norway

[7] Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, N-7034 Trondheim, Norway

[8] Univ Hosp, Rikshosp, Dept Internal Med, Unit Hematol & Stem Cell Transplantat, Oslo, Norway

来源：

ACTA HAEMATOLOGICA | 2009年 / 122卷 / 01期

关键词：

BCR-ABL; Chronic myelogenous leukemia; Imatinib; Multiplex RT-PCR; POLYMERASE-CHAIN-REACTION; RESIDUAL DISEASE DETECTION; ACUTE BASOPHILIC LEUKEMIA; CHRONIC-MYELOID-LEUKEMIA; FUSION TRANSCRIPT; CML PATIENT; GENE; IDENTIFICATION; RESISTANCE; DASATINIB;

D O I：

10.1159/000230037

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22. The majority of CML patients have a breakpoint in the major BCR region of the BCR gene giving rise to e13a2 or e14a2 BCR-ABL transcripts. Occasionally, other BCR breakpoints occur. The current report describes two e6a2 CML patients with imatinib treatment failure and unusual disease progression. One patient was Philadelphia chromosome positive and one was Philadelphia chromosome negative with an atypical BCR-ABL rearrangement, ins (22; 9). Copyright (C) 2009 S. Karger AG, Basel

引用

页码：11 / 16

页数：6

共 50 条

[1] A novel BCR-ABL, fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia
Hochhaus, A
Reiter, A
Skladny, H
Melo, JV
Sick, C
Berger, U
Guo, JQ
Arlinghaus, RB
Hehlmann, R
Goldman, JM
Cross, NCP
BLOOD, 1996, 88 (06) : 2236 - 2240
[2] e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Colla, S
Sammarelli, G
Voltolini, S
Crugnola, M
Sebastio, P
Giuliani, N
HAEMATOLOGICA, 2004, 89 (05) : 611 - 613
[3] Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
Donato, NJ
Wu, JY
Stapley, J
Lin, H
Arlinghaus, R
Aggarwal, B
Shishodin, S
Albitar, M
Hayes, K
Kantarjian, H
Talpaz, M
CANCER RESEARCH, 2004, 64 (02) : 672 - 677
[4] THE BCR-ABL GENE IN CHRONIC MYELOGENOUS LEUKEMIA
SAWYERS, CL
CANCER SURVEYS, 1992, 15 : 37 - 51
[5] Inadequate BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia
Stanek, E.
Aubert, R. E.
Sanders, C.
Frueh, F. W.
Yao, J.
Epstein, R. S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[6] BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.
Teitelbaum, A. H.
Henk, H. J.
Bollu, V.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[7] Induction of BCR-ABL mutations for acquired resistance in chronic myelogenous leukemia cells by imatinib
Yuan, Hongfeng
Gao, Chunggang
Bhatia, Ravi
Chen, WenYong
CANCER RESEARCH, 2009, 69
[8] Molecular breakpoint of BCR-ABL in chronic myeloid leukemia and imatinib response
不详
PHARMACOGENOMICS, 2010, 11 (09) : 1202 - 1203
[9] BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia
Gruenebach, Frank
Mirakaj, Valbona
Mirakaj, Valdete
Mueller, Martin R.
Bruemmendorf, Tim
Brossart, Peter
CANCER RESEARCH, 2006, 66 (11) : 5892 - 5900
[10] Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib
Ritchie, David S.
McBean, Michelle
Westerman, David A.
Kovalenko, Sergey
Seymour, John F.
Dobrovic, Alexander
BLOOD, 2008, 111 (05) : 2896 - 2898

← 1 2 3 4 5 →